{"doc_id": "33475701", "type of study": "Therapy", "title": "", "abstract": "Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.\nImportance : Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide.\nNeutralizing antibodies are a potential treatment for COVID-19.\nObjective : To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.\nDesign, Setting, and Participants : The BLAZE-1 study is a randomized phase 2/3 trial at 49 US centers including ambulatory patients (N\u2009=\u2009613) who tested positive for SARS-CoV-2 infection and had 1 or more mild to moderate symptoms.\nPatients who received bamlanivimab monotherapy or placebo were enrolled first (June 17-August 21, 2020) followed by patients who received bamlanivimab and etesevimab or placebo (August 22-September 3).\nThese are the final analyses and represent findings through October 6, 2020.\nInterventions : Patients were randomized to receive a single infusion of bamlanivimab (700 mg [n\u2009=\u2009101], 2800 mg [n\u2009=\u2009107], or 7000 mg [n\u2009=\u2009101]), the combination treatment (2800 mg of bamlanivimab and 2800 mg of etesevimab [n\u2009=\u2009112]), or placebo (n\u2009=\u2009156).\nMain Outcomes and Measures : The primary end point was change in SARS-CoV-2 log viral load at day 11 (\u00b14 days).\nNine prespecified secondary outcome measures were evaluated with comparisons between each treatment group and placebo, and included 3 other measures of viral load, 5 on symptoms, and 1 measure of clinical outcome (the proportion of patients with a COVID-19-related hospitalization, an emergency department [ED] visit, or death at day 29).\nResults : Among the 577 patients who were randomized and received an infusion (mean age, 44.7 [SD, 15.7] years; 315 [54.6%] women), 533 (92.4%) completed the efficacy evaluation period (day 29).\nThe change in log viral load from baseline at day 11 was -3.72 for 700 mg, -4.08 for 2800 mg, -3.49 for 7000 mg, -4.37 for combination treatment, and -3.80 for placebo.\nCompared with placebo, the differences in the change in log viral load at day 11 were 0.09 (95% CI, -0.35 to 0.52; P\u2009=\u2009.69) for 700 mg, -0.27 (95% CI, -0.71 to 0.16; P\u2009=\u2009.21) for 2800 mg, 0.31 (95% CI, -0.13 to 0.76; P\u2009=\u2009.16) for 7000 mg, and -0.57 (95% CI, -1.00 to -0.14; P\u2009=\u2009.01) for combination treatment.\nAmong the secondary outcome measures, differences between each treatment group vs the placebo group were statistically significant for 10 of 84 end points.\nThe proportion of patients with COVID-19-related hospitalizations or ED visits was 5.8% (9 events) for placebo, 1.0% (1 event) for 700 mg, 1.9% (2 events) for 2800 mg, 2.0% (2 events) for 7000 mg, and 0.9% (1 event) for combination treatment.\nImmediate hypersensitivity reactions were reported in 9 patients (6 bamlanivimab, 2 combination treatment, and 1 placebo).\nNo deaths occurred during the study treatment.\nConclusions and Relevance : Among nonhospitalized patients with mild to moderate COVID-19 illness, treatment with bamlanivimab and etesevimab, compared with placebo, was associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11; no significant difference in viral load reduction was observed for bamlanivimab monotherapy.\nFurther ongoing clinical trials will focus on assessing the clinical benefit of antispike neutralizing antibodies in patients with COVID-19 as a primary end point.\nTrial Registration : ClinicalTrials.gov Identifier: NCT04427501.\n", "Evidence Map": {"Enrollment": [{"term": "Mild to Moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 128}, {"term": "mild to", "negation": "affirmed", "UMLS": {}, "start": 201, "end": 208}, {"term": "ambulatory patients", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 136}, {"term": "positive for SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 159, "end": 192}, {"term": "1 or more", "negation": "affirmed", "UMLS": {}, "start": 201, "end": 210}, {"term": "mild", "negation": "affirmed", "UMLS": {}, "start": 211, "end": 215}, {"term": "nonhospitalized", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 49}, {"term": "mild to moderate COVID-19 illness", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 97}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 : A Randomized Clinical Trial .", "Evidence Elements": {"Participant": [{"term": "Mild to Moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 128}], "Intervention": [{"term": "Bamlanivimab", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 22, "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 0, "end": 12}], "has_relation": "N/A"}], "Outcome": [{"term": "Viral Load", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 85}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Importance : Coronavirus disease 2019 ( COVID-19 ) continues to spread rapidly worldwide .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Neutralizing antibodies are a potential treatment for COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Objective : To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) viral load in mild to moderate COVID-19 .", "Evidence Elements": {"Participant": [{"term": "mild to", "negation": "affirmed", "UMLS": {}, "start": 201, "end": 208}], "Intervention": [{"term": "bamlanivimab monotherapy", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 63, "has_procedure": [{"text": "bamlanivimab monotherapy", "maps_to": "C4763675:Monotherapy", "start": 0, "end": 24}], "has_relation": "N/A"}, {"term": "combination therapy with bamlanivimab and etesevimab", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 120, "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 25, "end": 37}, {"text": "etesevimab", "maps_to": "C5421804:etesevimab", "start": 42, "end": 52}], "has_procedure": [{"text": "combination therapy", "maps_to": "C0009429:combination therapy", "start": 0, "end": 19}], "has_relation": "combined_with (C0009429<->C5421805<->C5421804)"}], "Outcome": [{"term": "severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) viral load", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 197}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Design , Setting , and Participants : The BLAZE-1 study is a randomized phase 2 / 3 trial at 49 US centers including ambulatory patients ( N= 613 ) who tested positive for SARS-CoV-2 infection and had 1 or more mild to moderate symptoms .", "Evidence Elements": {"Participant": [{"term": "ambulatory patients", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 136}, {"term": "positive for SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 159, "end": 192}, {"term": "1 or more", "negation": "affirmed", "UMLS": {}, "start": 201, "end": 210}, {"term": "mild", "negation": "affirmed", "UMLS": {}, "start": 211, "end": 215}], "Intervention": [{"term": "BLAZE-1", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 49, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients who received bamlanivimab monotherapy or placebo were enrolled first ( June 17-August 21 , 2020 ) followed by patients who received bamlanivimab and etesevimab or placebo ( August 22-September 3 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "bamlanivimab monotherapy", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 46, "has_procedure": [{"text": "bamlanivimab monotherapy", "maps_to": "C4763675:Monotherapy", "start": 0, "end": 24}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 57, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "bamlanivimab", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 34, "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "etesevimab", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 168, "has_chemical": [{"text": "etesevimab", "maps_to": "C5421804:etesevimab", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 57, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "These are the final analyses and represent findings through October 6 , 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Interventions : Patients were randomized to receive a single infusion of bamlanivimab ( 700 mg [ n = 101 ] , 2800 mg [ n = 107 ] , or 7000 mg [ n = 101 ] ) , the combination treatment ( 2800 mg of bamlanivimab and 2800 mg of etesevimab [ n = 112 ] ) , or placebo ( n = 156 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "bamlanivimab", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 85, "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "combination treatment", "negation": "affirmed", "UMLS": {}, "start": 162, "end": 183, "has_procedure": [{"text": "treatment", "maps_to": "C0087111:treatment", "start": 12, "end": 21}], "has_relation": "N/A"}, {"term": "bamlanivimab", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 85, "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 0, "end": 12}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Main Outcomes and Measures : The primary end point was change in SARS-CoV-2 log viral load at day 11 ( \u00b14 days ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "change in SARS-CoV-2 log viral load", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 90}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Nine prespecified secondary outcome measures were evaluated with comparisons between each treatment group and placebo , and included 3 other measures of viral load , 5 on symptoms , and 1 measure of clinical outcome ( the proportion of patients with a COVID-19-related hospitalization , an emergency department [ ED ] visit , or death at day 29 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "each treatment", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 99, "has_procedure": [{"text": "treatment", "maps_to": "C0087111:treatment", "start": 5, "end": 14}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 117, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "viral load", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 163}, {"term": "symptoms", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 179}, {"term": "clinical outcome", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 215}, {"term": "proportion of patients with a COVID-19-related hospitalization , an emergency department [ ED", "negation": "affirmed", "UMLS": {}, "start": 222, "end": 315}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Results : Among the 577 patients who were randomized and received an infusion ( mean age , 44.7 [ SD , 15.7 ] years ; 315 [ 54.6 % ] women ) , 533 ( 92.4 % ) completed the efficacy evaluation period ( day 29 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The change in log viral load from baseline at day 11 was -3.72 for 700 mg , -4.08 for 2800 mg , -3.49 for 7000 mg , -4.37 for combination treatment , and -3.80 for placebo .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "700 mg", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 73, "has_relation": "N/A"}, {"term": "2800 mg", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 93, "has_relation": "N/A"}, {"term": "7000 mg", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 113, "has_relation": "N/A"}, {"term": "combination treatment", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 147, "has_procedure": [{"text": "treatment", "maps_to": "C0087111:treatment", "start": 12, "end": 21}], "has_relation": "N/A"}], "Outcome": [{"term": "change in log viral load", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 28}], "Observation": [{"term": "-3.72", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 62}, {"term": "-4.08", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 81}, {"term": "-3.49", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 101}, {"term": "-4.37", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 121}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "700 mg", "has_relation": "N/A"}, "Observation": "-3.72", "Outcome": "change in log viral load", "Count": ""}, {"Intervention": {"term": "2800 mg", "has_relation": "N/A"}, "Observation": "-4.08", "Outcome": "change in log viral load", "Count": ""}, {"Intervention": {"term": "7000 mg", "has_relation": "N/A"}, "Observation": "-3.49", "Outcome": "change in log viral load", "Count": ""}, {"Intervention": {"term": "combination treatment", "has_procedure": [{"text": "treatment", "maps_to": "C0087111:treatment", "start": 12, "end": 21}], "has_relation": "N/A"}, "Observation": "-4.37", "Outcome": "change in log viral load", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Compared with placebo , the differences in the change in log viral load at day 11 were 0.09 ( 95 % CI , -0.35 to 0.52 ; P =.69 ) for 700 mg , -0.27 ( 95 % CI , -0.71 to 0.16 ; P =.21 ) for 2800 mg , 0.31 ( 95 % CI , -0.13 to 0.76 ; P =.16 ) for 7000 mg , and -0.57 ( 95 % CI , -1.00 to -0.14 ; P =.01 ) for combination treatment .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 21, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "700 mg", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 139, "has_relation": "N/A"}, {"term": "2800 mg", "negation": "affirmed", "UMLS": {}, "start": 189, "end": 196, "has_relation": "N/A"}], "Outcome": [{"term": "differences in the change in log viral load", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 71}], "Observation": [{"term": "0.09", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 91}, {"term": "-0.27", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 147}, {"term": "0.31", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 203}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "0.09", "Outcome": "differences in the change in log viral load", "Count": ""}, {"Intervention": {"term": "700 mg", "has_relation": "N/A"}, "Observation": "0.09", "Outcome": "differences in the change in log viral load", "Count": ""}, {"Intervention": {"term": "700 mg", "has_relation": "N/A"}, "Observation": "-0.27", "Outcome": "differences in the change in log viral load", "Count": ""}, {"Intervention": {"term": "2800 mg", "has_relation": "N/A"}, "Observation": "-0.27", "Outcome": "differences in the change in log viral load", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "0.31", "Outcome": "differences in the change in log viral load", "Count": ""}, {"Intervention": {"term": "2800 mg", "has_relation": "N/A"}, "Observation": "0.31", "Outcome": "differences in the change in log viral load", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Among the secondary outcome measures , differences between each treatment group vs the placebo group were statistically significant for 10 of 84 end points .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "each treatment", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 73, "has_procedure": [{"text": "treatment", "maps_to": "C0087111:treatment", "start": 5, "end": 14}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 94, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "differences", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 50}, {"term": "end", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 148}], "Observation": [{"term": "statistically significant", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 131}], "Count": [{"term": "10 of 84", "negation": "affirmed", "UMLS": {}, "start": 136, "end": 144}]}, "Evidence Propositions": [{"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "statistically significant", "Outcome": "differences", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "The proportion of patients with COVID-19-related hospitalizations or ED visits was 5.8 % ( 9 events ) for placebo , 1.0 % ( 1 event ) for 700 mg , 1.9 % ( 2 events ) for 2800 mg , 2.0 % ( 2 events ) for 7000 mg , and 0.9 % ( 1 event ) for combination treatment .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 113, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "700 mg", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 144, "has_relation": "N/A"}, {"term": "2800 mg", "negation": "affirmed", "UMLS": {}, "start": 170, "end": 177, "has_relation": "N/A"}], "Outcome": [{"term": "proportion of patients with COVID-19-related hospitalizations or ED visits", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 78}], "Observation": [{"term": "5.8 % ( 9 events )", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 101}, {"term": "1.0 % ( 1 event )", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 133}, {"term": "1.9 % ( 2 events )", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 165}, {"term": "2.0", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 183}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "5.8 % ( 9 events )", "Outcome": "proportion of patients with COVID-19-related hospitalizations or ED visits", "Count": ""}, {"Intervention": {"term": "700 mg", "has_relation": "N/A"}, "Observation": "1.0 % ( 1 event )", "Outcome": "proportion of patients with COVID-19-related hospitalizations or ED visits", "Count": ""}, {"Intervention": {"term": "2800 mg", "has_relation": "N/A"}, "Observation": "1.9 % ( 2 events )", "Outcome": "proportion of patients with COVID-19-related hospitalizations or ED visits", "Count": ""}, {"Intervention": {"term": "700 mg", "has_relation": "N/A"}, "Observation": "2.0", "Outcome": "proportion of patients with COVID-19-related hospitalizations or ED visits", "Count": ""}, {"Intervention": {"term": "2800 mg", "has_relation": "N/A"}, "Observation": "2.0", "Outcome": "proportion of patients with COVID-19-related hospitalizations or ED visits", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Immediate hypersensitivity reactions were reported in 9 patients ( 6 bamlanivimab , 2 combination treatment , and 1 placebo ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "bamlanivimab", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 81, "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "combination treatment", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 107, "has_procedure": [{"text": "treatment", "maps_to": "C0087111:treatment", "start": 12, "end": 21}], "has_relation": "N/A"}], "Outcome": [{"term": "Immediate hypersensitivity reactions", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 36}], "Observation": [], "Count": [{"term": "9 patients", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 64}, {"term": "6", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 68}, {"term": "2", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 85}]}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "No deaths occurred during the study treatment .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "deaths", "negation": "negated", "UMLS": {}, "start": 3, "end": 9}], "Observation": [], "Count": [{"term": "No", "negation": "negated", "UMLS": {}, "start": 0, "end": 2}]}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Conclusions and Relevance : Among nonhospitalized patients with mild to moderate COVID-19 illness , treatment with bamlanivimab and etesevimab , compared with placebo , was associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11 ; no significant difference in viral load reduction was observed for bamlanivimab monotherapy .", "Evidence Elements": {"Participant": [{"term": "nonhospitalized", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 49}, {"term": "mild to moderate COVID-19 illness", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 97}], "Intervention": [{"term": "bamlanivimab", "negation": "negated", "UMLS": {}, "start": 115, "end": 127, "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 0, "end": 12}], "has_relation": "N/A"}, {"term": "etesevimab", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 142, "has_chemical": [{"text": "etesevimab", "maps_to": "C5421804:etesevimab", "start": 0, "end": 10}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 159, "end": 166, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "SARS-CoV-2 viral load", "negation": "affirmed", "UMLS": {}, "start": 230, "end": 251}, {"term": "viral load reduction", "negation": "negated", "UMLS": {}, "start": 293, "end": 313}], "Observation": [{"term": "statistically significant reduction", "negation": "affirmed", "UMLS": {}, "start": 191, "end": 226}, {"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 267, "end": 289}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "bamlanivimab", "has_chemical": [{"text": "bamlanivimab", "maps_to": "C5421805:bamlanivimab", "start": 0, "end": 12}], "has_relation": "N/A"}, "Observation": "statistically significant reduction", "Outcome": "SARS-CoV-2 viral load", "Count": ""}, {"Intervention": {"term": "etesevimab", "has_chemical": [{"text": "etesevimab", "maps_to": "C5421804:etesevimab", "start": 0, "end": 10}], "has_relation": "N/A"}, "Observation": "statistically significant reduction", "Outcome": "SARS-CoV-2 viral load", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "statistically significant reduction", "Outcome": "SARS-CoV-2 viral load", "Count": ""}, {"Intervention": [], "Observation": "significant difference", "Outcome": "viral load reduction", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Further ongoing clinical trials will focus on assessing the clinical benefit of antispike neutralizing antibodies in patients with COVID-19 as a primary end point .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Trial Registration : ClinicalTrials.gov Identifier : NCT04427501 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}